Edinburgh Research Explorer

Prof David Harrison

UoE Honorary staff

  1. 2019
  2. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031

    Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In : Scientific Reports. 9, 1, 7643.

    Research output: Contribution to journalArticle

  3. 2018
  4. Raman spectroscopy investigation of biochemical changes in tumour spheroids with ageing and after treatment with staurosporine

    Jamieson, L. E., Harrison, D. J. & Campbell, C. J., 23 Sep 2018, In : Journal of biophotonics. p. e201800201

    Research output: Contribution to journalArticle

  5. Acquired and intrinsic resistance to colorectal cancer treatment

    Briffa, R., Langdon, S., Grech, G. & Harrison, D., 16 May 2018, Colorectal Cancer: Diagnosis, Screening and Management. Chen, J. (ed.). InTech

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

  6. ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing in South-East of Scotland

    Kheng, Y. C., Walsh, K., Williams, L., Wallace, W. & Harrison, D., 1 Mar 2018, In : Journal of the Royal College of Physicians of Edinburgh. 48, 1

    Research output: Contribution to journalArticle

  7. 2017
  8. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

    Meehan, J., Ward, C., Turnbull, A., Wills, J., Finch, A., Jarman, E., Xintaropoulou, C., Martinez Perez, C., Gray, M., Pearson, M., Mullen, P., Supuran, C. T., Carta, F., Harrison, D., Kunkler, I. & Langdon, S., 17 Apr 2017, In : Oncotarget.

    Research output: Contribution to journalArticle

  9. Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002

    Goltsov, A., Tashkandi, G., Langdon, S. P., Harrison, D. J. & Bown, J. L., 15 Jan 2017, In : European Journal of Pharmaceutical Sciences. 97

    Research output: Contribution to journalArticle

  10. 2016
  11. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

    Khalil, H. S., Langdon, S., Goltsov, A., Soininen, T., Harrison, D., Bown, J. & Deeni, Y., 4 Oct 2016, In : Oncotarget.

    Research output: Contribution to journalArticle

  12. Targeted SERS nanosensors measure physicochemical gradients and free energy changes in live 3D tumor spheroids

    Jamieson, L. E., Camus, V. L., Bagnaninchi, P. O., Fisher, K. M., Stewart, G. D., Nailon, W. H., McLaren, D. B., Harrison, D. J. & Campbell, C. J., 6 Sep 2016, In : Nanoscale. 8, 37, p. 16710-16718 8 p.

    Research output: Contribution to journalArticle

  13. Novel histopathologic feature identified through image analysis augments stage II colorectal cancer clinical reporting

    Caie, P. D., Zhou, Y., Turnbull, A. K., Oniscu, A. & Harrison, D. J., 12 Jul 2016, In : Oncotarget. 7, 28, p. 44381-44394 14 p.

    Research output: Contribution to journalArticle

  14. Could molecular pathology testing in lung cancer be more cost effective?

    Walsh, K., Kheng, Y. C., Oniscu, A., Harrison, D. & Wallace, W., 7 Jul 2016, In : Journal of Clinical Pathology.

    Research output: Contribution to journalArticle

Previous 1 2 3 4 5 6 7 8 ...20 Next